Clinical Trials Logo

Filter by:
NCT ID: NCT06435702 Not yet recruiting - Prostate Cancer Clinical Trials

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

Start date: June 1, 2024
Phase:
Study type: Observational

This study is an open, prospective, single-center observational clinical study to evaluate the efficacy and safety of immediate adjuvant ADT with darotarolimide in the treatment of patients with positive lymph nodes after radical prostatectomy for prostate cancer.

NCT ID: NCT06435260 Not yet recruiting - Pancreatic Cancer Clinical Trials

To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of locally advanced pancreatic cancer.

NCT ID: NCT06435104 Not yet recruiting - Early Breast Cancer Clinical Trials

Aromatherapy in the Treatment of Early Breast Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

Breast cancer is a major threat to women's health, and chemotherapy is one of the most important treatment method. Chemotherapy is cytotoxic , and has a positive tumor immune effect. However, it is worth noting that anxiety caused by breast cancer itself and adverse reactions of chemotherapy not only affects the patients' quality of life, but also reduces the treatment compliance and even survival benefits of patients. Previous literatures have shown that aromatherapy may improve chemotherapy-induced anxiety and even affect anti-tumor immunity. Therefore,we envisage that aromatherapy conbimed with chemotherapy in the treatment of breast cancer in clinical practice has the advantages of improving efficacy and survival. However, there is still a lack of relevant clinical studies. We planned to design a prospective clinical trial to evaluate the efficacy and safety of aromatherapy combined with chemotherapy on anxiety, relevant sympathetic neurotransmitters and tumor immunity in breast cancer patients.

NCT ID: NCT06434961 Not yet recruiting - Clinical trials for Secondary Hyperparathyroidism

The Trial of SHR6508 in Secondary Hyperparathyroidism

Start date: June 2024
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

NCT ID: NCT06434610 Not yet recruiting - Clinical trials for Platinum-resistant Recurrent Ovarian Cancer

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Start date: June 30, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.

NCT ID: NCT06434597 Not yet recruiting - Clinical trials for Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Start date: June 30, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.

NCT ID: NCT06434467 Not yet recruiting - Clinical trials for T-lymphoblastic Lymphoma

The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Start date: May 2024
Phase: Phase 3
Study type: Interventional

This is a single-arm, open-label, multicenter, phase III clinical study that aims to evaluate the efficacy and safety of Nelarabine injection in the treatment of refractory or recurrent T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) in both children and adults. The trial includes 83 subjects, consisting of 35 adults and 48 children, and aims to evaluate the composite complete response rate (CCR) within 2 cycles, assessed by the Independent Review Committee (IRC), following treatment with Nelarabine injection for children and adults with refractory or recurrent T-ALL and T-LBL. The sample size of this study is estimated according to the treatment period of 4 cycles.

NCT ID: NCT06434389 Not yet recruiting - Hypofibrinogenemia Clinical Trials

A Point-of-care Electrochemical-based Device for Rapid Detection of Fibrinogen on Type A Aortic Dissection Surgery

Start date: June 1, 2024
Phase:
Study type: Observational [Patient Registry]

This study compares the results of the existing fibrinogen concentration monitoring technology to the Electrochemical-based device, a point-of-care and rapid method,using a small amount of extra blood obtained in Type A Aortic Dissection Surgery.

NCT ID: NCT06434090 Not yet recruiting - Colorectal Cancer Clinical Trials

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Start date: June 5, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the efficacy and safety of liposomal irinotecan plus bevacizumab in irinotecan-refractory metastatic colorectal cancer

NCT ID: NCT06433609 Not yet recruiting - Clinical trials for Advanced Breast Cancer

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Start date: June 2024
Phase: Phase 2
Study type: Interventional

Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811 and SHR-A1921 combined with adebrelimab in HER2-negative advanced breast cancer.